Literature DB >> 21338384

Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers.

Paul V Johnson1, Barbra M Blair, Skye Zeller, Camille N Kotton, Elizabeth L Hohmann.   

Abstract

Listeria monocytogenes vectors have shown promise for delivery of viral and tumor antigens in animals. We used two mutant vector strains deleted for actA/plcB (BMB72) and actA/inlB (BMB54), and engineered both strains to secrete a heterologous nucleoprotein antigen from the Influenza A virus. Strains were evaluated in vitro and in mice. Twenty-two healthy volunteers received single oral doses of either strain in a physiological study of safety, shedding, and immunogenicity. Volunteers were observed in the hospital for seven days and had daily blood cultures, routine safety blood tests (complete blood count with differential; hepatic and renal function), and fecal cultures; none had fever, positive blood cultures, prolonged shedding, or serious or unexpected events. Four of 12 volunteers who received the actA/plcB-deleted strain had minor, transient, asymptomatic serum transaminase elevations (maximum increase 1.4× upper normal). Six of six volunteers who received ≥4 × 10(9) colony forming units had detectable mucosal immune responses to listerial antigens, but not to the vectored influenza antigen. Approximately half the volunteers had modest interferon-γ ELISpot responses to a complex listerial antigen, but none had increases over their baseline responses to the influenza antigen. Comparison with prior work suggests that foreign antigen expression, and perhaps also freezing, may adversely affect the organisms' immunogenicity.
© 2011 The Societies and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21338384      PMCID: PMC3082616          DOI: 10.1111/j.1348-0421.2011.00322.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  39 in total

1.  Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo.

Authors:  P M Taylor; B A Askonas
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

2.  Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

Authors:  M M Levine; J B Kaper; D Herrington; J Ketley; G Losonsky; C O Tacket; B Tall; S Cryz
Journal:  Lancet       Date:  1988-08-27       Impact factor: 79.321

3.  Isolation of Listeria monocytogenes small-plaque mutants defective for intracellular growth and cell-to-cell spread.

Authors:  A N Sun; A Camilli; D A Portnoy
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

4.  Identification of an intestinal immune response using peripheral blood lymphocytes.

Authors:  B D Forrest
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

5.  Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the influenza A virus matrix protein.

Authors:  S Y Sauma; M C Gammon; M A Bednarek; B Cunningham; W E Biddison; J D Hermes; G Porter; S Tamhankar; J C Hawkins; B L Bush
Journal:  Hum Immunol       Date:  1993-08       Impact factor: 2.850

6.  Adoptive transfer of immunity to Listeria monocytogenes. The influence of in vitro stimulation on lymphocyte subset requirements.

Authors:  D K Bishop; D J Hinrichs
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

7.  Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors.

Authors:  Peter Lauer; Man Yin Nora Chow; Martin J Loessner; Daniel A Portnoy; Richard Calendar
Journal:  J Bacteriol       Date:  2002-08       Impact factor: 3.490

8.  Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity.

Authors:  H Shen; M K Slifka; M Matloubian; E R Jensen; R Ahmed; J F Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

9.  DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

Authors:  Suzanne L Epstein; Terrence M Tumpey; Julia A Misplon; Chia-Yun Lo; Lynn A Cooper; Kanta Subbarao; Mary Renshaw; Suryaprakash Sambhara; Jacqueline M Katz
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

10.  Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes.

Authors:  G Ikonomidis; Y Paterson; F J Kos; D A Portnoy
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  15 in total

Review 1.  Clinical development of Listeria monocytogenes-based immunotherapies.

Authors:  Dung T Le; Thomas W Dubenksy; Dirk G Brockstedt
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

2.  A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.

Authors:  Qingmei Jia; Richard Bowen; Jacob Sahakian; Barbara Jane Dillon; Marcus A Horwitz
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

Review 3.  Engineering bacteria for diagnostic and therapeutic applications.

Authors:  David T Riglar; Pamela A Silver
Journal:  Nat Rev Microbiol       Date:  2018-02-05       Impact factor: 60.633

Review 4.  Engineering living therapeutics with synthetic biology.

Authors:  Andres Cubillos-Ruiz; Tingxi Guo; Anna Sokolovska; Paul F Miller; James J Collins; Timothy K Lu; Jose M Lora
Journal:  Nat Rev Drug Discov       Date:  2021-10-06       Impact factor: 84.694

5.  Transcutaneous immunization of healthy volunteers with an attenuated Listeria monocytogenes vaccine strain and cholera toxin adjuvant.

Authors:  Elizabeth H Eypper; Paul V Johnson; Eva I Purro; Elizabeth L Hohmann
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

Review 6.  Vaccines: from empirical development to rational design.

Authors:  Christine Rueckert; Carlos A Guzmán
Journal:  PLoS Pathog       Date:  2012-11-08       Impact factor: 6.823

Review 7.  An evaluation of the emerging vaccines against influenza in children.

Authors:  Harish Nair; Eva Lau; W Brooks; Ang Seong; Evropi Theodoratou; Lina Zgaga; Tanvir Huda; Suresh S Jadhav; Igor Rudan; Harry Campbell
Journal:  BMC Public Health       Date:  2013-09-17       Impact factor: 3.295

8.  Recombinant influenza vaccines.

Authors:  E S Sedova; D N Shcherbinin; A I Migunov; Iu A Smirnov; D Iu Logunov; M M Shmarov; L M Tsybalova; B S Naroditskiĭ; O I Kiselev; A L Gintsburg
Journal:  Acta Naturae       Date:  2012-10       Impact factor: 1.845

Review 9.  Pre-existing immunity against vaccine vectors--friend or foe?

Authors:  Manvendra Saxena; Thi Thu Hao Van; Fiona J Baird; Peter J Coloe; Peter M Smooker
Journal:  Microbiology       Date:  2012-11-22       Impact factor: 2.777

Review 10.  Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery.

Authors:  Ivan Y C Lin; Thi Thu Hao Van; Peter M Smooker
Journal:  Vaccines (Basel)       Date:  2015-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.